DGAP-News: INJEX Pharma AG: Changes in the prospectus schedule - decision on listing approval by the Frankfurt Stock Exchange and the commencement of share trading are postponed
(firmenpresse) - DGAP-News: INJEX Pharma AG / Key word(s): Miscellaneous
INJEX Pharma AG: Changes in the prospectus schedule - decision on
listing approval by the Frankfurt Stock Exchange and the commencement
of share trading are postponed
18.03.2013 / 14:51
---------------------------------------------------------------------
Corporate News: Changes in the prospectus schedule - decision on listing
approval by the Frankfurt Stock Exchange and the commencement of share
trading are postponed
Berlin, March 18, 2013 - INJEX Pharma AG announces that the timetable of
the securities prospectus, that was approved on February 26, 2013, is
changing. The approval decision of the Frankfurt Stock Exchange and the
commencement of share trading which should have taken place today are
postponed.
According to the German Prospectus law, if a significant new factor arises
during the relevant period, the company shall submit a supplementary
prospectus containing details of the new factor to the Federal Financial
Supervisory Authority (BaFin) for its approval. The relevant period begins
when the prospectus is approved by the BaFin and ends when trading in the
securities on the regulated market begins. After the approval of the
prospectus on February 26th, 2013, a significant new factor arose which
leads to a supplementary prospectus.
The approval decision of the Frankfurt Stock Exchange and the commencement
of share trading are postponed due to the obligation to write a
supplementary prospectus. The postponement was initiated at the request of
INJEX Pharma AG.
INJEX Pharma AG will set up as fast as possible the supplementary
prospectus. As long as the supplementary prospectus is not filed with
BaFin, the approval decision of the Frankfurt Stock Exchange and the
commencement of share trading will not take place. We endeavour to produce
the draft within a reasonable timeframe, but more importantly will make
sure, that all new events will be addressed appropriately.
For further information on INJEX Pharma AG and its subsidiaries, please
refer to www.injex.com.
For further questions please contact our Investor Relations team directly:
INJEX Pharma AG
Investor Relations Team
t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 499
ir(at)injex.com
INJEX Pharma AG:
INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and
INJEX Vertrieb Deutschland GmbH are specialized in the development,
manufacturing and marketing in the medical technology segment and in the
cosmetics and beauty markets. The Group's core business areas are the
needle-free INJEX30 system and the product line SHIREEN in the beauty
market. The main markets of the Group are North America, China, India,
Russia and Europe.
End of Corporate News
---------------------------------------------------------------------
18.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: INJEX Pharma AGBuckower Damm 114
12349 Berlin
Germany
Phone: +49 89 24 41 18 - 223
Fax: +49 89 24 41 18 - 499
E-mail: ir(at)injex.de
Internet: www.injex.de
ISIN: DE000A0STYL7
WKN: A0STYL
Listed: Regulierter Markt in Frankfurt (General Standard)
Notierung vorgesehen / designated to be listed
End of News DGAP News-Service
---------------------------------------------------------------------
204253 18.03.2013
Themen in dieser Pressemitteilung:
injex-pharma-ag-changes-in-the-prospectus-schedule
decision-on-listing-approval-by-the-frankfurt-stock-exchange-and-the-commencement-of-share-trading-are-postponed
Unternehmensinformation / Kurzprofil:
Datum: 18.03.2013 - 14:51 Uhr
Sprache: Deutsch
News-ID 240348
Anzahl Zeichen: 4200
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: INJEX Pharma AG: Changes in the prospectus schedule - decision on listing approval by the Frankfurt Stock Exchange and the commencement of share trading are postponed"
steht unter der journalistisch-redaktionellen Verantwortung von
INJEX Pharma AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
